PARNAX LAB
|
PARNAX LAB Last 5 Year Financial Ratios History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 7.50 | 8.40 | -0.43 | -3.43 | 3.88 |
CEPS(Rs) | 13.20 | 14.39 | 5.64 | 1.81 | 8.38 |
DPS(Rs) | - | - | - | - | - |
Book NAV/Share(Rs) | 54.11 | 47.24 | 38.26 | 38.56 | 42.01 |
Tax Rate(%) | 29.70 | 32.66 | -332.77 | -48.23 | 28.45 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 13.72 | 14.13 | 11.04 | 6.74 | 9.40 |
EBIT Margin(%) | 10.28 | 10.73 | 5.55 | 2.76 | 7.82 |
Pre Tax Margin(%) | 7.33 | 7.52 | -0.09 | -2.06 | 4.25 |
PAT Margin (%) | 5.15 | 5.07 | -0.40 | -3.06 | 3.04 |
Cash Profit Margin (%) | 9.05 | 8.66 | 5.33 | 1.62 | 6.55 |
Performance Ratios | |||||
ROA(%) | 5.78 | 6.36 | -0.34 | -2.89 | 3.63 |
ROE(%) | 15.91 | 20.93 | -1.11 | -8.51 | 9.69 |
ROCE(%) | 15.20 | 17.34 | 5.83 | 3.27 | 11.59 |
Asset Turnover(x) | 1.12 | 1.26 | 0.84 | 0.94 | 1.20 |
Sales/Fixed Asset(x) | 1.63 | 1.85 | 1.18 | 1.42 | 1.94 |
Working Capital/Sales(x) | -29.31 | -16.38 | -4.77 | -9.00 | 179.46 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.61 | 0.54 | 0.84 | 0.70 | 0.52 |
Receivable days | 71.83 | 61.33 | 80.64 | 80.93 | 63.50 |
Inventory Days | 45.31 | 34.39 | 44.46 | 37.57 | 27.08 |
Payable days | 75.70 | 57.63 | 74.68 | 73.02 | 51.70 |
Valuation Parameters | |||||
PER(x) | 6.94 | 15.68 | - | - | 8.69 |
PCE(x) | 3.94 | 9.15 | 3.46 | 6.68 | 4.02 |
Price/Book(x) | 0.96 | 2.79 | 0.51 | 0.31 | 0.80 |
Yield(%) | - | - | - | - | - |
EV/Net Sales(x) | 0.64 | 1.16 | 0.79 | 0.62 | 0.64 |
EV/Core EBITDA(x) | 4.54 | 8.09 | 6.98 | 8.39 | 5.68 |
EV/EBIT(x) | 6.26 | 10.80 | 14.20 | 22.58 | 8.23 |
EV/CE(x) | 0.74 | 1.23 | 0.67 | 0.56 | 0.74 |
M Cap / Sales | 0.36 | 0.79 | 0.18 | 0.11 | 0.26 |
Growth Ratio | |||||
Net Sales Growth(%) | 2.81 | 81.03 | -5.51 | -12.38 | 3.11 |
Core EBITDA Growth(%) | 1.71 | 129.99 | 43.18 | -42.47 | 11.23 |
EBIT Growth(%) | -1.51 | 250.08 | 89.69 | -69.03 | 15.82 |
PAT Growth(%) | 4.54 | 2,378.51 | 87.57 | -188.22 | 213.01 |
EPS Growth(%) | -10.65 | 2,062.37 | 87.51 | -188.34 | 213.02 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.82 | 1.41 | 1.71 | 1.54 | 1.17 |
Current Ratio(x) | 0.91 | 0.88 | 0.65 | 0.80 | 1.02 |
Quick Ratio(x) | 0.57 | 0.63 | 0.45 | 0.59 | 0.78 |
Interest Cover(x) | 3.48 | 3.34 | 0.98 | 0.57 | 2.19 |
Total Debt/Mcap(x) | 0.85 | 0.51 | 3.35 | 4.90 | 1.46 |
Compare Financial Ratios of peers of PARNAX LAB
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
PARNAX LAB | ₹131.6 Cr | -0.6% | -17.7% | 64.2% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹367,290.0 Cr | -0.9% | 0.9% | 62.6% | Stock Analytics | |
CIPLA | ₹113,357.0 Cr | 3.5% | 4.2% | 51.8% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹111,134.0 Cr | 12.2% | 18% | 103.8% | Stock Analytics | |
DIVIS LABORATORIES | ₹104,235.0 Cr | 0.8% | 5.6% | 19.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹97,001.5 Cr | -1% | -2.4% | 28.4% | Stock Analytics |
PARNAX LAB Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
PARNAX LAB | -0.6% |
-17.7% |
64.2% |
SENSEX | 1.7% |
1.5% |
18.7% |
You may also like the below Video Courses